Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
11.59
-0.11 (-0.94%)
At close: Jul 19, 2024, 12:00 AM
11.97
+0.38 (3.28%)
Pre-market: Jul 22, 2024, 7:43 AM EDT
Y-mAbs Therapeutics Employees
Y-mAbs Therapeutics had 100 employees as of December 31, 2023. The number of employees decreased by 47 or -31.97% compared to the previous year.
Employees
100
Change (1Y)
-47
Growth (1Y)
-31.97%
Revenue / Employee
$844,990
Profits / Employee
-$216,660
Market Cap
508.60M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Community Health Systems | 61,000 |
Sharecare | 3,352 |
GRAIL, LLC | 1,360 |
Valneva SE | 676 |
Jin Medical International | 245 |
COMPASS Pathways | 186 |
Heron Therapeutics | 126 |
PureTech Health | 90 |
YMAB News
- 1 hour ago - Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB - GlobeNewsWire
- 20 days ago - Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer - GlobeNewsWire
- 5 weeks ago - Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm - Accesswire
- 6 weeks ago - Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting - GlobeNewsWire
- 6 weeks ago - Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer - GlobeNewsWire
- 7 weeks ago - Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting - GlobeNewsWire
- 7 weeks ago - Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - GlobeNewsWire